HOVON 156

About this trial

This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Patient Profile

Patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, St James’s Hospital, University Hospital Limerick, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: HOVON 156
Number: 19-16
Full Title:

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Principal Investigator: Dr Janusz Krawczyk (University Hospital Galway)
Type: Collaborative
Sponsor:

Collaborative Group Trial sponsored by HOVON (based in The Netherlands)

Recruitment Started: Global: December 2019
Ireland: May 2021
Global Recruitment Target: 768
Ireland Recruitment Target: 50